Market News Archives - Vista Partners LLC

Home Sales Near 30-Year Lows—But Buyers Are Quietly Plotting a Comeback? -( $SPY $DIA $HD )

by John F. Heerdink, Jr. 2 hours ago 58Views 0Likes

US existing-home sales may be slumping toward historic lows, but the housing market is quietly laying the groundwork for a surprisingly upbeat spring—provided buyers, sellers, and the Federal Reserve can stick to the same script. Home Sales Skid, But Not Off the…

Apple Bites Back in China: How iPhone Turned a Market Slump into a Power Move -( $AAPL $DIA $SPY $QQQ )

by John F. Heerdink, Jr. 12 hours ago 65Views 0Likes

Apple’s (AAPL) latest China sales story reads less like a tech obituary and more like a plot twist: in a sharply contracting smartphone market, the iPhone has quietly slipped back into a lead role, powered by price discipline, bigger storage, and a…

When Bangles Meet Bankers: Inside India’s Glittering Gold-Loan Boom -( $GLD )

by John F. Heerdink, Jr. 13 hours ago 53Views 0Likes

India’s gold-backed lending boom is turning family heirlooms into the country’s most hardworking asset class, as households and small businesses increasingly march into bank branches with bangles instead of balance sheets. Rising gold prices, looser lending rules, and a vast, underutilized stockpile…

Serina Therapeutics Secures 30 Million Reasons Wall Street Is Warming to Parkinson’s Innovation -( $SER $IBB $XBI )

by John F. Heerdink, Jr. 21 hours ago 244Views 0Likes

Serina Therapeutics (NYSE: SER) (www.serinatx.com) seems to have have just traded itself into Wall Street’s good graces, pairing fresh capital with a late-session pop that suggests investors are finally starting to connect the dots between polymer chemistry and portfolio returns. Parkinson’s Bet…

Fiber, Funding, and GPUs: Why This Nokia–Nvidia–KGPCo Triangle Should Be on Investors’ Screens -( $NOK $NVDA )

by John F. Heerdink, Jr. 21 hours ago 86Views 0Likes

Nvidia’s (NVDA) billion-dollar bet on Nokia (NOK) adds an AI-powered tailwind to what was already a quietly strategic broadband story for KGPCo and BEAD-focused operators. With GPUs now effectively hitching a ride on fiber builds, the network economy just picked up a…

March 18, 2026 – Oil, Inflation and a Grumpy Fed: Why Wall Street Just Marked Down Its Soft-Landing Fantasy -( $HTFL $LULU $VIX Rise!)

by John F. Heerdink, Jr. 22 hours ago 2681Views 0Likes

Stocks staged a Fed-day post St. Patty's Day hungover tantrum Wednesday, as investors discovered that “higher for longer” still means exactly what it sounds like. Indexes and Rates The Dow industrials fell sharply, at one point flirting with a 700‑plus point slide,…

Interest Rates on Hold, Nerves Not So Much: How the Fed Is Playing Economic Jenga -( $SPY $VIX $NVDA $SWMR )

by John F. Heerdink, Jr. 24 hours ago 158Views 0Likes

The Federal Reserve’s latest rate decision landed not with a bang, but with the kind of carefully measured thud Wall Street has come to admire: steady, data-dependent, and just hawkish enough to keep the bond vigilantes awake. Fed Holds the Line as…

Amazon’s $600 Billion Cloud Dream: Can Wall Street Handle This Much AI Optimism? -( $AMZN $SPY )

by John F. Heerdink, Jr. 2 days ago 95Views 0Likes

Amazon is effectively telling Wall Street that its cloud is no longer just a utility—it is the monetization engine of the AI era, with Andy Jassy sketching a path to an eye‑popping (600) billion dollars in annual AWS revenue by 2036. The…

March 17, 2026 – Gold Glitters, Yields Flinch: A St. Paddy’s Market Recap With a Wink -( $EPRX $GLD $INTG $LMND $OPEN $SOAR Rise!)

by John F. Heerdink, Jr. 2 days ago 2598Views 0Likes

Wall Street spent St. Patrick’s Day edging back into the green, as investors raised a cautious toast to the Federal Reserve and NVIDIA’s AI ambitions rather than to rapid-fire rate cuts. Indices and macro mood US stocks advanced for a second straight…

Eupraxia’s Six-Month Data Put EP-104GI On The Map – And EPRX On More Screens -( $EPRX $IBB $SNY $XBI )

by John F. Heerdink, Jr. 2 days ago 148Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) is behaving less like a sleepy small-cap from Victoria and more like a company auditioning for prime time in the EoE treatment lineup. With six‑month symptom data from its RESOLVE trial now in hand and a fortified balance…

Market News

Your Guide To Staying Informed In The Markets